
Janssen acquires XO1 Limited
Janssen Pharmaceuticals has acquired XO1 Limited, a privately held asset-centric virtual biopharmaceutical company founded to develop the anti-thrombin antibody ichorcumab. Financial terms of the transaction have not been disclosed. Ichorcumab is a recombinant human antibody developed to mimic the activity of a human antibody which appears to produce an anticoagulated


